Immunitas Therapeutics
Company Details
Status: Private
Employees: 11-50
Location:
Waltham, Massachusetts, United States
Type:
sample
Technology:
sample
sample
sample
About: Immunitas is an immuno-oncology therapeutics company advancing multiple programs to the clinic. Immunitas’ programs are derived from a cross-functional, highly integrated, single cell genomics platform that enables rapid target identification and validation in parallel with antibody discovery and engineering. IMT-009, a first-in-class T & NK cell modulator targeting CD161, is being developed for the treatment of solid tumors and hematological malignancies. The company was founded with leading scientists from Dana Farber, MGH, the Broad, and MIT. In 2019, Immunitas raised a $39M Series A from a strong syndicate of investors including the Longwood Fund, Hillhouse, NVF, Leaps by Bayer, and M Ventures.
Unlock access to company contacts, hot leads, and drug pipelines.
Log in or create a free account now!
Immunitas Therapeutics | Active clinical trials on ClinicalTrials.gov
Active Clinical Trials Count | 0
No Active Trials Found On ClinicalTrials.gov.